Rep. David Davis: Really Sucking Up For
Gregory RU-486ish Campaign Funds
The Sunday, May 14, 2006 morning edition of the Johnson City Press reported within the article brief "Former senator joining Crowe as campaign co-chair" that the 2006 1st Congressional District republican candidate David Davis is appointing "...former State Senator Jim Holcomb as his campaign chairman."
Holcomb is quoted within the article brief as commenting about Davis' legislative experience as that "...David has demonstrated the ability to effectively articulate issues that are of concern to working families in Tennessee."
Persumably, Holcomb is referring to the August 1999 King Pharmaceuticals legislative airlift aboard a corporate jet of Rep. Davis and several other Northeast Tennessee members of the Tennessee General members to a Nashville meeting with the then TennCare Director Brian Lapps, seeking to place the Monarch Pharmaceuticals (a King Pharma subsidary) branded Altace (TM) on the TennCare PDL (preferred drug list). At the time of the King legislative airlift, Holcomb was employed as a King Pharmaceuticals lobbyist.
Altace (TM) was added to the TennCare PDL during September of 1999 and former TennCare Director Lapps resigned later during the same month.
Altace (TM) was targeted for consumer boycott by many anti-abortion groups beginning during the late 1980s, as the cardiac drug was owned by the German parent pharmaceutical drug company Hoechst AE. Another Hoechst-owned French pharmaceutical company in France developed and later manfactured the RU-486 abortion drug.
During the summer of 1994, the National Right To Life Committee lauched a U.S. consumer boycott against Hoechst produced products, specifically listing Altace(TM) as a targeted item. By the middle of 1995, form King Pharmaceuticals President Jefferson "Jeff" Gregory (brother of former CEO John M. Gregory) started his negotations with Hoechst toward acquiring the Altace (TM) line and finally arriving at an agreement with Hoechst that secured Altace (TM) U.S. distribution rights for King.
King Pharmaceuticals, Inc. finally acquired the U.S. distribution rights for Altace (TM) under the Monarch Pharmaceuticals brand from Hoechst Marion Roussell (HMR) of Kansas City, Missouri during late December 1998.
Holcomb first served as the political action committte treasurer for former King Pharmaceuticals, Inc. CEO John M. Gregory's Tennessee Conservative PAC while working as "governmental affairs manager" at the Gregory- owned Leitner Pharmaceuticals during the 2004 Tennessee state elections.
Holcomb was hired by Leitener Pharmaceuticals in February, 2002.
Holcomb is quoted within the article brief as commenting about Davis' legislative experience as that "...David has demonstrated the ability to effectively articulate issues that are of concern to working families in Tennessee."
Persumably, Holcomb is referring to the August 1999 King Pharmaceuticals legislative airlift aboard a corporate jet of Rep. Davis and several other Northeast Tennessee members of the Tennessee General members to a Nashville meeting with the then TennCare Director Brian Lapps, seeking to place the Monarch Pharmaceuticals (a King Pharma subsidary) branded Altace (TM) on the TennCare PDL (preferred drug list). At the time of the King legislative airlift, Holcomb was employed as a King Pharmaceuticals lobbyist.
Altace (TM) was added to the TennCare PDL during September of 1999 and former TennCare Director Lapps resigned later during the same month.
Altace (TM) was targeted for consumer boycott by many anti-abortion groups beginning during the late 1980s, as the cardiac drug was owned by the German parent pharmaceutical drug company Hoechst AE. Another Hoechst-owned French pharmaceutical company in France developed and later manfactured the RU-486 abortion drug.
During the summer of 1994, the National Right To Life Committee lauched a U.S. consumer boycott against Hoechst produced products, specifically listing Altace(TM) as a targeted item. By the middle of 1995, form King Pharmaceuticals President Jefferson "Jeff" Gregory (brother of former CEO John M. Gregory) started his negotations with Hoechst toward acquiring the Altace (TM) line and finally arriving at an agreement with Hoechst that secured Altace (TM) U.S. distribution rights for King.
King Pharmaceuticals, Inc. finally acquired the U.S. distribution rights for Altace (TM) under the Monarch Pharmaceuticals brand from Hoechst Marion Roussell (HMR) of Kansas City, Missouri during late December 1998.
Holcomb first served as the political action committte treasurer for former King Pharmaceuticals, Inc. CEO John M. Gregory's Tennessee Conservative PAC while working as "governmental affairs manager" at the Gregory- owned Leitner Pharmaceuticals during the 2004 Tennessee state elections.
Holcomb was hired by Leitener Pharmaceuticals in February, 2002.
posted by Elmer Gantry at
10:50 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home